INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$21.51M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$21.18M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 178 insiders$2.77M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

73,431 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
16
BL
Brown Justin LPresident/Southwest Gas Corp.
SWXSouthwest Gas Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$246K
3,028 sh
Jan 9, 2026
Page 1514 of 1836
← PrevNext →
Jan 13, 2026
traded Jan 9, 2026
+4d
SEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$758K
1,480 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$304K
575 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
ST
Stonehocker TimothyChief Technology Officer
SOUNSOUNDHOUND AI, INC.
Open-market sale · 10b5-1 plan
SELL$356K
29.7K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$507K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$396K
766 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$307K
588 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$493K
960 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FC
Follmann ChristianChief Operating Officer
HTGCHercules Capital, Inc.
Tax withholding
F$141K
7,580 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$482K
937 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$269K
521 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$561K
1,066 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$492K
960 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$628K
1,199 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$254K
473 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$480K
913 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$822K
1,560 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
BZ
Botelho Kiersten ZazaChief Legal Officer & CCO
HTGCHercules Capital, Inc.
Tax withholding
F$102K
5,510 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$598K
1,135 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$561K
1,094 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$503K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$700K
1,335 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$440K
846 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$324K
600 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$814K
1,578 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$280K
539 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$383K
732 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$782K
1,489 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
100 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$692K
1,345 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$366K
691 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

15
KE
Kelly Timothy EdwinChief Financial Officer
PRAXPraxis Precision Medicines, Inc.
Tax withholding
F$260K
943 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

15
MH
Meyer Seth HChief Financial Officer
HTGCHercules Capital, Inc.
Tax withholding
F$297K
16.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

15
LH
Litinsky James H.Director, Chairman and CEO
MPMP Materials Corp. / DE
Tax withholding
F$2.24M
35.1K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

15
LH
Litinsky James H.Director, Chairman and CEO
MPMP Materials Corp. / DE
Tax withholding
F$2.50M
38.2K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

15
LH
Litinsky James H.Director, Chairman and CEO
MPMP Materials Corp. / DE
Tax withholding
F$1.72M
26.3K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$289K
4,067 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$294K
9,119 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$281K
3,933 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
CV
Caldwell Nick V.Chief Product Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$176K
25.1K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence